Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eric Stakebake

Physician Assistant Lakeland, FL Physician Assistant

NPI 1619215738 CMS profile 10776527

6500 N Socrum Loop Rd Ste 200, Lakeland, FL 33809

Open in the dashboard

General payments

$8,044

322 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Stakebake of Lakeland, FL is reported in the CMS Open Payments database as having received $8,044 across 322 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,241 96
2024 General $2,475 110
2023 General $868 44
2022 General $914 40
2021 General $1,546 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Stakebake
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Eric Stakebake were reported at $2,241. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Eric Stakebake Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,546 $132 $37–$438 $132
2022 $914 $155 $48–$522 $149
2023 $868 $167 $52–$557 $160
2024 $2,475 $178 $55–$600 $164
2025 $2,241 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,547 104 payments
  2. Allergan Inc. $750 1 payment
  3. Janssen Biotech, Inc. $745 29 payments
  4. Regeneron Healthcare Solutions, Inc. $657 12 payments
  5. UCB, Inc. $564 18 payments
  6. Pfizer Inc. $487 30 payments
  7. Novartis Pharmaceuticals Corporation $345 20 payments
  8. Genzyme Corporation $334 13 payments
  9. Lilly USA, LLC $324 11 payments
  10. E.R. Squibb & Sons, L.L.C. $309 11 payments
  11. Other $1,984 73 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,992 315 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $750 1 payment
  3. Education $303 6 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $879 6 payments
  2. RINVOQ $809 49 payments
  3. TREMFYA $690 26 payments
  4. Bimzelx $564 18 payments
  5. DUPIXENT Inflammation And Immunology $560 9 payments
  6. SKYRIZI $366 29 payments
  7. LITFULO $336 26 payments
  8. DUPIXENT Immunology $334 13 payments
  9. SOTYKTU $284 10 payments
  10. CIBINQO $250 26 payments
  11. Other $3,509 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

3,003

Median for Physician Assistant: 241

Drug cost

$1,698,392

Median for Physician Assistant: $4,110

Branded share of claims

10.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 99 $371,549
Skyrizi Pen Risankizumab-Rzaa Brand 17 $354,817
Skyrizi Risankizumab-Rzaa Brand 16 $337,305
Cosentyx Unoready Pen Secukinumab Brand 18 $181,740
Dupixent Syringe Dupilumab Brand 39 $153,323
Humira(Cf) Pen Adalimumab Brand 14 $133,745
Opzelura Ruxolitinib Phosphate Brand 39 $79,347
Jublia Efinaconazole Brand 26 $20,051
Ciclopirox Generic 574 $16,133
Ammonium Lactate Generic 454 $13,504

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $291
$291 — —
Bimzelx
  • UCB, Inc. $290
$290 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $271
$271 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $146
  • GENZYME CORPORATION $82
$227 138 —
RINVOQ
  • AbbVie, Inc. $191
$191 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

322 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record